Statement: No participants of the primary trial had a Progression Free Survival over 1 year.
Primary_evidence: Outcome Measurement:    Progression Free Survival   Progression free survival was based in investigator-determined progressive disease (PD) and calculated from the date of randomization to the date of PD or the date of death, whichever occurred first. Participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the clinical cutoff. For PD or death with a missing interval immediately preceding the event, progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval. Participants who withdrew from the study (withdrawal of consent or lost to follow-up) without progression were censored at the time of the last disease assessment.   Time frame: From the date of randomization to the date of disease progression (PD) or death, whichever occurred first (up to 8.4 years) Results 1:    Arm/Group Title: Standard of Care (SOC)   Arm/Group Description: Participants received standard supportive care as packed red blood cells (RBC) transfusion as per Investigator's discretion.   Overall Number of Participants Analyzed: 1048   Median (95% Confidence Interval)   Unit of Measure: Months  7.4        (7.1 to 7.6) Results 2:    Arm/Group Title: Epoetin Alfa   Arm/Group Description: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously (SC) once a week.   Overall Number of Participants Analyzed: 1050   Median (95% Confidence Interval)   Unit of Measure: Months  7.4        (6.9 to 7.6)